BioInvent International
LUND, SE / ACCESSWIRE / December 8, 2021 / BioInvent International (STO:BINV)
- BioInvent's pipeline expanding to four drug candidates in five clinical trials
Lund, Sweden - December 8, 2021 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has submitted a Clinical Trial Application (CTA) for the novel, fully human FcyRIIB-blocking antibody, BI-1607.
BI-1607 targets FcyRIIB but is modified in its Fc region to alter its affinity for Fc receptors. By selectively blocking FcyRIIB, BI-1607 enhances the activity of other therapeutic monoclonal antibodies, whose mechanism-of-action involves depletion of tumors or immune suppressive cells. Understanding the biology of FcR/Fc interactions was essential for generating BI-1607, which has a clearly differentiated profile from BioInvent's lead drug candidate BI-1206.
BioInvent intends to explore the activity of BI-1607 in advanced solid tumors and antibody combinations supported by strong preclinical data.
"We are pleased to have completed this step in the development. BI-1607 is a very promising approach given its ability to enhance anti-cancer immunity and approval of the CTA will expand the BioInvent pipeline to four drug candidates in five clinical trials, further underlining the productivity of our technology platform," said Martin Welschof, CEO of BioInvent.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy. In addition to BI-1607, the company has three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/676499/BioInvent-has-Submitted-a-CTA-for-a-Phase-12a-trial-of-BI-1607-a-Novel-anti-FcyRIIB-Antibody-for-the-Treatment-of-Patients-with-Solid-Tumors
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Loar Holdings Inc. Announced The Completion of its Acquisition of LMB Fans & Motors26.12.2025 14:00:00 CET | Press release
WHITE PLAINS, NEW YORK / ACCESS Newswire / December 26, 2025 / Loar Holdings Inc. (NYSE:LOAR) ("Loar," "we," "our," or "the Company") today announced the completion of its acquisition of LMB Fans & Motors ("LMB") for €367 million, plus the assumption of debt, paid in cash at closing. Founded more than 60 years ago, LMB is a global leader in designing and manufacturing customized, high-performance fans and motors. With decades of expertise and nearly 100% of its revenue derived from proprietary designs, LMB offers over 2,000 unique products, including fans, blowers, motors, and specialized rotating machines. Its fans and brushless motors are widely used across aerospace and defense platforms. LMB employs more than 75 team members worldwide, including those at its headquarters and manufacturing facility in Malemort-sur-Corrèze, France. The transaction was completed following clearance under the French foreign direct investment screening procedure by the Ministry of Economy and Finance. L
SK tes Announces Grand Opening of New Shannon Facility, Marking a Milestone for Sustainable Technology in Ireland22.12.2025 15:00:00 CET | Press release
SHANNON, IE / ACCESS Newswire / December 22, 2025 / SK tes, a global leader in secure technology lifecycle and IT asset disposition (ITAD) services, is delighted to announce the grand opening of its state-of-the-art facility in Shannon, County Clare. The opening event, to be held on Jan. 15, 2026, marks the culmination of a journey that began with the company's announcement in 2025 of its plans to establish a purpose-built facility in one of Ireland's fastest-growing technology regions. The grand opening will be hosted by Jin Mo Lee, SK tes Group CEO at SK tes and guest of honor, Minister Timmy Dooley will cut the ribbon to officially open the site. Minister Dooley, a Clare native, serves as Minister of State for Climate, Energy and the Environment. Minister Dooley's leadership in climate, energy, and environmental policy is especially relevant as Ireland continues to attract major global data center infrastructure and technology companies, while placing increased emphasis on sustainab
Saat & Saat Acquires Turkish Apparel Leader Aydinli Group, Expanding U.S. Polo Assn. Markets Across Turkey, the Middle East, Eastern Europe, and North Africa22.12.2025 13:00:00 CET | Press release
WEST PALM BEACH, FL AND ISTANBUL, TURKEY / ACCESS Newswire / December 22, 2025 / USPA Global is pleased to announce the acquisition of Aydinli Hazir Giyim San. Tic. A.S. (Aydinli Group) by HRK Holding A.S. (Saat & Saat). Both entities are licensing partners of U.S. Polo Assn., which is USPA Global's multi-billion-dollar sports brand and the official brand of the United States Polo Association (USPA). As one of the brand's largest partners, the acquisition of Aydinli provides access to more than 50 countries across Turkey, the Middle East, Eastern Europe, and North Africa. With this acquisition of Aydinli, Saat & Saat is expanding the company's regional portfolio alongside its very successful watch business by entering the global apparel industry. With more than nearly 450 U.S. Polo Assn. stores and multiple branded digital sites, U.S. Polo Assn. will continue its record growth. Aydinli is currently one of the leading retail powerhouses in the region, with significant growth potential a
Parallel Society Reveals Lineup for 2026 Lisbon Edition - A Cross-Genre Mashup of Cultural and Tech Pioneers22.12.2025 10:30:00 CET | Press release
Apparat (live) Kode9, Moses Boyd, Gilles Peterson and Clark head to Lisbon for new indie festival Parallel Society. LISBON, PT / ACCESS Newswire / December 22, 2025 / Parallel Society has revealed the first wave of artists for its 2026 edition in Lisbon, Portugal. The two-day event begins on 6th March, and the music starts on 7th March with a programme spanning the UK jazz revolution (Moses Boyd), experimental bass culture (Kode9, Calibre), avant-electronic (Apparat), and cultural ambassadors (Gilles Peterson), with many more acts still to be announced. A culture-first counterpoint to the corporate consolidation sweeping the global festival landscape, Parallel Society is independent, led by the community, and not for profit. With more than 60% of the lineup sourced from Lisbon's active and diverse homegrown talent pool, the event actively supports the city's underground music scenes. Ahead of Parallel Society's music and cultural programme on Day 2, Day 1, the "[un]conference", invites
Rainer Maria Morita Named "Transformational Leader of the Year 2025" at UK House of Lords22.12.2025 10:25:00 CET | Press release
Recognized for redefining executive career transition and human value creation in the AI era with his globally renowned Morita Method(R) LONDON, GB / ACCESS Newswire / December 22, 2025 / Global executive advisor and bestselling author, Rainer Maria Morita, has been awarded "Transformational Leader of the Year 2025 in the category of Global Hidden Job Market Advisory at the prestigious Global Leadership Conclave 2025, held at the iconic UK House of Lords, Parliament of the United Kingdom. The award recognizes Rainer's pioneering work in redefining leadership, employment, and human value creation in the age of artificial intelligence. With more than two decades of experience across executive search, executive career transition advisory and leadership consulting, Rainer has become a globally respected authority on the Hidden Job Market - the unadvertised ecosystem where over 90% of executive opportunities are created. As the creator of The Morita Method®, Rainer has guided thousands of s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom